Advanced nano-based strategies for mRNA tumor vaccine  

作　　者：Yangqi Qu Jingjing Xu Tong Zhang Qinjun Chen Tao Sun Chen Jiang 

机构地区：[1]Key Laboratory of Smart Drug Delivery(Ministry of Education),Minhang Hospital,State Key Laboratory of Medical Neurobiology,Department of Pharmaceutics,School of Pharmacy,Fudan University,Shanghai 201203,China

出　　处：《Acta Pharmaceutica Sinica B》2024年第1期170-189,共20页药学学报（英文版）

基　　金：This work was supported by National Natural Science Funds of China(Nos.92059110 and 81872808);Development Fund for Shanghai Talents(No.2020090,China);Natural Science Foundation of Shanghai Science and Technology Innovation Plan(No.22ZR1414100,China);FDU 2025-Excellence Program Fund,Project Supported by Shanghai Municipal Science and Technology Major Project(No.2018SHZDZX01,China);ZJLab,Shanghai Post-doctoral Excellence Program(No.2033016,China);China Postdoctoral Science Foundation Funded Project(No.2023M730711).

摘　　要：Tumor vaccine is a promising strategy for cancer immunotherapy by introducing tumor antigens into the body to activate specific anti-tumor immune responses.Along with the technological breakthroughs in genetic engineering and delivery systems,messenger ribonucleic acid(mRNA)technology has achieved unprecedented development and application over the last few years,especially the emergency use authorizations of two mRNA vaccines during the COVID-19 pandemic,which has saved countless lives and makes the world witness the powerful efficacy of mRNA technology in vaccines.However,unlike infectious disease vaccines,which mainly induce humoral immunity,tumor vaccines also need to activate potent cellular immunity to control tumor growth,which creates a higher demand for mRNA delivery to the lymphatic organs and antigen-presenting cells(APCs).Here we review the existing bottlenecks of mRNA tumor vaccines and advanced nano-based strategies to overcome those challenges,as well as future considerations of mRNA tumor vaccines and their delivery systems.

关 键 词：mRNA vaccine NANOPARTICLE Tumor vaccine Delivery system Stability TARGETING TRANSFECTION IMMUNOGENICITY 

分 类 号：R73[医药卫生—肿瘤] R329[医药卫生—临床医学]